한빛사
>
한빛사논문
한빛사논문
- 조회105
Nat. Commun., Published: 25 March 2025 | https://doi.org/10.1038/s41467-025-58006-y
Kinetically activating nanovaccine mimicking multidimensional immunomodulation of natural infection for broad protection against heterologous viruses in animal models
Sang Nam Lee1,5, Young-Il Kim2,5, Jaemoo Kim2,5, D. K. Haluwana3,5, Ryounho Eun1,5, Sei Hyun Park1, Janghun Heo1, Juryeon Gil2, Yebin Seong3, Min-Ho Lee4, Young-Woock Noh4, Jong-Soo Lee3, Young Ki Choi2 & Yong Taik Lim1
1Department of Nano Engineering, SKKU Advanced Institute of Nanotechnology (SAINT), School of Chemical Engineering, and Biomedical Institute for Convergence at SKKU, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419, Republic of Korea.
2Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute (KVRI), Institute for Basic Science (IBS), 55, Expo-ro, Yuseong-gu, Daejeon 34126, Republic of Korea.
3College of Veterinary Medicine, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.
4New Drug Development Center, Osong Medical Innovation Foundation, 123, Osongsaengmyeong-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28160, Republic of Korea.
5These authors contributed equally: Sang Nam Lee, Young-Il Kim, Jaemoo Kim, D. K. Haluwana, Ryounho Eun.
Corresponding authors
Correspondence to Jong-Soo Lee, Young Ki Choi or Yong Taik Lim.
1Department of Nano Engineering, SKKU Advanced Institute of Nanotechnology (SAINT), School of Chemical Engineering, and Biomedical Institute for Convergence at SKKU, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419, Republic of Korea.
2Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute (KVRI), Institute for Basic Science (IBS), 55, Expo-ro, Yuseong-gu, Daejeon 34126, Republic of Korea.
3College of Veterinary Medicine, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.
4New Drug Development Center, Osong Medical Innovation Foundation, 123, Osongsaengmyeong-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28160, Republic of Korea.
5These authors contributed equally: Sang Nam Lee, Young-Il Kim, Jaemoo Kim, D. K. Haluwana, Ryounho Eun.
Corresponding authors
Correspondence to Jong-Soo Lee, Young Ki Choi or Yong Taik Lim.
Abstract
Immunity by vaccination can protect human against heterologous viruses. However, protective abilities of artificial vaccines are still weaker than natural infections. Here we develop a kinetically engineered vaccine (KE-VAC) that mimics the multidimensional immunomodulation in natural infections via dynamic activation of antigen presenting cells with masked TLR7/8 agonist and sustained supplies of antigens and adjuvants to lymph nodes, leading to follicular helper T and germinal centre B cell activation in vaccinated mice. KE-VAC demonstrates superior efficacy than traditional alum and mRNA vaccines, achieving a 100% survival rate with increased neutralizing antibodies titers and polyfunctional CD8+ T cells, recognizing heterologous SARS-CoV-2 variants, and inducing broad and long-term protection against multiple strains of influenza viruses. Prime/boost vaccination with KE-VAC also protect aged ferrets from severe fever with thrombocytopenia syndrome virus infection, with no virus detected in any organs at day 6 p.i. The efficacy of KE-VAC across various pathogens thus highlights its potential as an effective vaccine against emerging infectious risks.
논문정보
- Research article
- 2025년 03월 (BRIC 등록일 2025-03-26)
- 국내(교신)+국외 연구진
- 의약학 > 면역의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 논문보기
